Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Share News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bramson vehicle buys more shares in F&C

Tue, 15th Mar 2011 17:05

F&C Asset Management chairman Edward Bramson's investment vehicle SIGA LP has acquired more shares in the asset management company. Bramson was appointed chairman of F&C last month after a shareholder coup removed the previous incumbent, along with another non-executive, and appointed three new directors, including Bramson. SIGA has acquired 125,852 shares at 77.59p each. That cost £97,649 and followed the purchase of 265,000 shares at 77.79p each on Friday. SIGA has invested just over £300,000 in F&C shares in the past few days. SIGA owns around 18.1% of F&C and this is also deemed to be Bramson's holding. SIGA uses funds supplied by AIM-quoted Sherborne Investors to invest in F&C. The F&C share price has been falling back in recent weeks and it is around 10% lower over the past month. There are concerns that some asset management clients will desert F&C."Our focus now is to build on the things that work well at F&C and to improve the group's financial performance, which will create value for shareholders," according to Bramson when the company released its 2010 figures last Wednesday. A profit before tax a year ago was turned to a loss of £19.2m this time. The previous year's number benefited from a £27.9m debt exchange programme. Assets under management rose to £105.8bn from £97.8bn at the end of 2009, helped by £4.2bn from the acquisition of Thames River Capital in September. Net revenues increased to £243.2m from £225.1m, including performance related management fees of £12.9m, down from £18.7m the year before. Top Director Buys Travis Perkins (TPK) Director name: Mr Geoff CooperAmount purchased: 16,395 @ 968.19p Value: £158,735F&C Asset Management (FCAM) Director name: Mr Edward BramsonAmount purchased: 125,852 @ 77.59p Value: £97,649Travis Perkins (TPK) Director name: Mr Paul N Hampden SmithAmount purchased: 9,856 @ 968.19p Value: £95,425Travis Perkins (TPK) Director name: Mr John P CarterAmount purchased: 9,856 @ 968.19p Value: £95,425Travis Perkins (TPK) Director name: Mr Andrew PikeAmount purchased: 2,666 @ 968.19p Value: £25,812CLS Holdings (CLI) Director name: Mr H O Thomas LundqvistAmount purchased: 3,500 @ 650.00p Value: £22,750Anite (AIE) Director name: Mr David Hurst-BrownAmount purchased: 30,000 @ 65.55p Value: £19,665Anite (AIE) Director name: Mr Nigel CliffordAmount purchased: 30,000 @ 65.55p Value: £19,665e-Therapeutics (ETX) Director name: Mr Steve SelfAmount purchased: 50,000 @ 36.50p Value: £18,250Anite (AIE) Director name: Mr Richard AmosAmount purchased: 25,000 @ 65.55p Value: £16,388Top Director SellsSchroders (SDR) Director name: Mr Alan BrownAmount sold: 32,154 @ 1,734.00p Value: £557,550Prudential (PRU) Director name: Mr Mike WellsAmount sold: 31,478 @ 718.75p Value: £226,248Mondi (MNDI) Director name: Mr Peter OswaldAmount sold: 62,090 @ 553.26p Value: £343,519Novae Group (NVA) Director name: Mr Jeremy AdamsAmount sold: 65,612 @ 387.90p Value: £254,509Novae Group (NVA) Director name: Mr Oliver CorbettAmount sold: 65,612 @ 387.90p Value: £254,509Novae Group (NVA) Director name: Mr Matthew K FoshAmount sold: 65,612 @ 387.90p Value: £254,509Mondi (MNDI) Director name: Mr David A HathornAmount sold: 32,998 @ 553.26p Value: £182,565Mondi (MNDI) Director name: Mr Andrew KingAmount sold: 10,550 @ 553.26p Value: £58,369Mondi (MNDI) Director name: Ms Carol HuntAmount sold: 10,153 @ 553.26p Value: £56,172
More News
20 Mar 2018 16:14

UK Earnings, Trading Statements Calendar - Next 7 Days

Wednesday 21 March KingfisherFull Year ResultsAlpha FXFull Year In SportFull 22

Read more
9 Jan 2017 08:49

E-Therapeutics Hires Amgen Director As New Chief Executive

Read more
6 Oct 2016 11:23

DIRECTOR DEALINGS: e-Therapeutics Non-Executive Acquires Shares

Read more
14 Sep 2016 11:23

e-Therapeutics Development Director Steve Self To Step Down

Read more
13 Jul 2016 09:13

E-Therapeutics Chairman Takes On Executive Duties As CEO Steps Down

Read more
1 Jun 2016 08:03

e-Therapeutics Offer For Searchbolt Now Wholly Unconditional

Read more
25 May 2016 08:18

e-Therapeutics Focused On Validation Of Drug Discovery Platform

Read more
18 May 2016 15:05

AGM, EGM Calendar - Week Ahead

Read more
12 May 2016 11:13

DIRECTOR DEALINGS: E-Therapeutics Non-Executive Acquires Shares

Read more
11 May 2016 09:06

e-Therapeutics To Buy Searchbolt For GBP2.3 Million (ALLISS)

Read more
22 Mar 2016 11:40

E-Therapeutics Loss Widens As Active Projects Increase

Read more
15 Mar 2016 16:15

Earnings, Trading Statements Calendar - Week Ahead

Read more
15 Feb 2016 10:43

WINNERS & LOSERS SUMMARY: Reckitt Benckiser Results Please Investors

Read more
15 Feb 2016 09:45

E-Therapeutics depression drug trials miss targets

(ShareCast News) - Drug trials results for e-Therapeutics' depression treatment were not as successful as had been hoped, sending shares in the company sharply lower. Phase IIb clinical trials of the company's ETS6103 product did not achieve the aim of matching the efficacy of existing tricyclic ant

Read more
15 Feb 2016 08:20

E-Therapeutics Shares Drop As ETS6103 Trials Miss Primary Endpoint

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.